Skip to main content
. 2013 Mar 5;1(3):403–410. doi: 10.3892/mco.2013.85

Figure 2.

Figure 2

Kaplan-Meier disease-specific survival curves for bladder cancer patients receiving combined trimodality therapy, stratified by (A) excision repair cross-complementing group 1 (ERCC1) expression (P=0.023, log-rank test); (B) X-ray repair cross-complementing group 1 (XRCC1) expression (P=0.025); (C) apurinic/apyrimidinic endonuclease 1 (APE1) expression (P=0.29); and (D) combined ERCC1 and XRCC1 expression (P=0.0091).